GALECTIN THERAPEUTICS INC.

GALT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-16.2M $-21.4M $-20.0M $-15.8M $-12.1M $-9.7M $-10.9M $-5.6M
Depreciation & Amortization $1.0K $7.0K $7.0K $10.0K $12.0K $9.0K $9.0K $12.0K
Depreciation $3.0K $6.0K
Amortization $1.0K $7.0K $7.0K $8.0K $7.0K $6.0K $3.0K
Stock-Based Compensation $1.1M $2.5M $3.4M $4.1M $3.8M $2.8M $3.2M $1.9M
Net Cash from Operating Activities $-15.9M $-16.4M $-17.0M $-12.4M $-7.5M $-7.5M $-5.7M $-3.1M
Investing Activities
Capital Expenditures $0 $0 $0 $5.0K $5.0K
Business Acquisitions
Net Cash from Investing Activities $0 $64.0K $-15.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $3.6M $8.6M $10.4M $6.2M $8.7M
Net Change in Cash $-12.3M $-10.5M $-3.3M $18.6M $1.1M $3.0M $506.0K $5.6M
Free Cash Flow $-17.0M $-12.4M $-7.5M $-7.5M $-5.7M
← Newer Page 2 of 2 Older →